Copper chelation efficacy of alginate/chitosan based D-penicillamine nanoparticles in rat model of non-Wilsonian brain copper toxicosis
Objective: To evaluate the copper (Cu) chelation efficacy of orally administered D-penicillamine loaded nanoparticles to that of conventional D-penicillamine therapy for 90 days in Wistar…Classification and recommendation of nonpharmacological therapies for Parkinson’s disease
Objective: A multidisciplinary specialized treatment including physiotherapy, speech and language therapy, occupational therapy (OT) associated to the ideal pharmacological treatment and surgical is recommended to…Multi-modal recruitment strategy leads to expeditious enrollment in STEADY-PD III
Objective: To review a successful multi-modal recruitment strategy in a clinical trial of early untreated PD patients. Background: STEADY-PD III is a multicenter NINDS funded…Transcranial versus root repeated magnetic stimulation as a treatment of psychogenic movement disorders
Objective: To determine whether the beneficial effect of repeated transcranial magnetic stimulation (rTMS) in psychogenic movement disorders (PMDs) is the consequence of a cortical functioning…Global implementation of efficacious voice treatment for Parkinson’s disease: LSVT LOUD: Germany®
Objective: This project was designed to evaluate the implementation of an efficacious voice treatment (LSVT LOUD) developed in the USA and designed to improve speech…Effect of right DLPFC-repetitive transcranial magnetic stimulation (rTMS) on tardive dyskinesia in patients with psychosis
Objective: The index study was done to examine any change in tardive dyskinesia, cognitive function and psychopathology following high frequency rTMS of the right Dorsolateral…Combined stimulation of STN and SNr for resistant freezing of gait in Parkinson’s disease (STN+SNr) – A multicenter randomized controlled trial
Objective: 54 patients with idiopathic Parkinson's disease and freezing of gait resistant to subthalamic nucleus stimulation and dopaminergic medication will be included into this German-wide…KINECT 3: A randomized, double-blind, placebo-controlled phase 3 trial of valbenazine (NBI-98854) for tardive dyskinesia
Objective: To assess the efficacy, safety and tolerability of valbenazine (NBI-98854) for Tardive Dyskinesia (TD). Background: Tardive dyskinesia (TD) is a persistent and often disabling…RE-024: Mechanism of action and efficacy in non-clinical models
Objective: To confirm the mechanism of action of RE-024, and evaluate its activity in human cellular models and brain penetration in animal models. Background: Pantothenate…Detailed evaluation of dyskinesias using multiple endpoints in a randomized, placebo-controlled trial of Parkinson’s disease patients with motor fluctuations
Objective: To analyze all dyskinesia data from a Phase 2b trial of fluctuating Parkinson patients in order to understand the overall impact a study drug…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.